| Market Capitalization (Millions $) |
24 |
| Shares
Outstanding (Millions) |
420 |
| Employees |
6 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-5 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Provectus Biopharmaceuticals Inc is a biotechnology company that focuses on developing innovative therapies for cancer and dermatological conditions. The company specializes in developing small molecule drugs and biologics that target specific molecular pathways involved in the progression of these diseases.
Provectus Biopharmaceuticals is best known for its drug candidate PV-10, which is being developed for the treatment of skin cancer, including metastatic melanoma. PV-10 is a selective small molecule drug that is injected directly into tumors, causing them to shrink or disappear. The drug has demonstrated promising results in clinical trials, showing high rates of complete response and minimal side effects.
In addition to its work on PV-10, Provectus Biopharmaceuticals is also involved in developing other drug candidates for various cancer types and dermatological conditions. The company utilizes its expertise in oncology, immunology, and molecular biology to develop novel therapies that have the potential to address unmet medical needs.
Overall, Provectus Biopharmaceuticals Inc is a biotechnology company that is dedicated to developing innovative therapies for cancer and dermatological conditions, with a particular focus on personalized medicine and targeted therapies.
Company Address: 800 S. Gay Street Knoxville 37929 TN
Company Phone Number: 594-5999 Stock Exchange / Ticker: PVCT
|
10.81%